Evidence map›Paper›PMID 35888745›Full record

ArticleMetabolites2022

Metabolome Features of COPD: A Scoping Review.

Suneeta Godbole, Russell P Bowler

Open access · goldAbstract readScoping Review
In one paragraph

Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Identifying Biomarkers for Chronic Obstructive Pulmonary Disease in the Salivary Metabolome.International journal of chronic obstructive pulmonary disease · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Suneeta GodboleDepartment of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-7358-2078
Russell P BowlerDivision of Medicine, National Jewish Health, Denver, CO 80206, USA.
Colorado School of Public Health · USNational Jewish Health · US

Funding

Metabolic profiles of COPD phenotypesP20HL113445 · NHLBI · NATIONAL JEWISH HEALTH · PI BOWLER, RUSSELL PAUL · 2012 to 2016
$4.7M
Biomarker of Lung Disease in African AmericansR01HL137995 · NHLBI · NATIONAL JEWISH HEALTH · PI BOWLER, RUSSELL PAUL, KECHRIS-MAYS, KATHERINA · 2018 to 2021
$3.4M
Multi-omic networks associated with COPD progression in TOPMed CohortsR01HL152735 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI BANAEI-KASHANI, FARNOUSH, BOWLER, RUSSELL PAUL · 2020 to 2023
$3.1M
Metabolome and proteome profiles of emphysema and airway diseaseR01HL095432 · NHLBI · NATIONAL JEWISH HEALTH · PI BOWLER, RUSSELL PAUL · 2009 to 2012
$1.6M
NHLBI NIH HHS P20 HL113445NHLBI NIH HHS R01 HL095432NHLBI NIH HHS R01 HL137995NHLBI NIH HHS R01 HL152735
6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is a complex heterogeneous disease state with multiple phenotypic presentations that include chronic bronchitis and emphysema. Although COPD is a lung disease, it has systemic manifestations that are associated with a dysregulated metabolome in extrapulmonary compartments (e.g., blood and urine). In this scoping review of the COPD metabolomics literature, we identified 37 publications with a primary metabolomics investigation of COPD phenotypes in human subjects through Google Scholar, PubMed, and Web of Science databases. These studies consistently identified a dysregulation of the TCA cycle, carnitines, sphingolipids, and branched-chain amino acids. Many of the COPD metabolome pathways are confounded by age and sex. The effects of COPD in young versus old and male versus female need further focused investigations. There are also few studies of the metabolome's association with COPD progression, and it is unclear whether the markers of disease and disease severity are also important predictors of disease progression.

Indexed as

chronic obstructive pulmonary disease (COPD)emphysemaexacerbationsmetabolomics

Identifiers

PMID35888745
PMCPMC9324381
OpenAlexW4286634219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.